3rd Aug 2020 06:57
Benchmark Holdings PLC - Sheffield, England-based aquaculture genetics, health and nutrition company - Announces sale of vaccine manufacturing facility at Braintreee, UK, to Cell and Gene Therapy Catapult for GBP16 million. Transaction forms part of a GBP100 million investment by the UK government to develop the Cell and Gene Therapy Catapult Manufacturing Innovation Center to manufacture millions of doses of Covid-19 vaccines per month. Benchmark Chief Executive Trond Williksen said: "This is an important step in our strategy of becoming a streamlined, profitable business focused on our key areas of competency."
Current stock price: 40.01 pence
Year-to-date change: down 8.8%
By Greg Roxburgh; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
Benchmark Holdings